A potent small molecule inhibitor to disrupt LMP1 and LMP2 oncogenic pathways and the origin of tumor-initiating cells could potentially be a novel and independent prognostic modality and therapeutic target for patients with EBV-associated NPC. This evidence concerns the gene PDLIM7 and neoplasm.